Aclarion, Inc.

Aclarion Publishes CEO Shareholder Letter Highlighting Continued Scan Volume Growth and Advancing Clinical Program in Third Quarter 2026

Aclarion published its Q3 2026 CEO shareholder letter reporting 85% year-over-year scan volume growth in the quarter and 117% growth for the first nine months of 2026. The clinical program advanced with the CLARITY trial expanded to eleven sites under revised enrollment criteria meant to speed recruitment, while the European Spine Journal published peer-reviewed data supporting MRS as an alternative to provocative discography. The company holds $14.2 million in cash, which it says funds the 300-patient CLARITY trial with runway into the second half of 2027; an enrollment and initial readout timing update is expected by year-end.

•12d ago

Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites

Aclarion added NYU Langone Health as the eleventh clinical site in its CLARITY trial network for Nociscan. The CLARITY study is a 300-patient, prospective, randomized, multi-center trial evaluating Nociscan in patients undergoing fusion or TDR surgery for discogenic low back pain, with a 12-month VAS Back primary endpoint. NYU Langone's Spine Center, ranked No. 1 in neurology and neurosurgery by U.S. News & World Report, serves more than 25,000 patients annually — a high-volume enrollment asset, though the announcement carries no new data.

•1mo ago

Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site

Aclarion added the University of Arizona College of Medicine – Phoenix as a new clinical site for its CLARITY trial, bringing the total number of active enrollment sites to ten. The CLARITY trial is a 300-patient, prospective, randomized study evaluating Nociscan's ability to improve surgical outcomes for chronic low back pain, with primary endpoints measuring pain reduction at 12 months. The company anticipates an internal data readout and public disclosure of early interim results in Q4 2026.

•2mo ago

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering multi-voxel prescription for lumbar disc evaluation, a key component of its Nociscan workflow. The innovation is designed to improve the precision of MRS data capture by accurately positioning sampling locations within the lumbar disc, which aims to reduce scan time and the need for repeat scans. Once issued, the patent will extend Aclarion's intellectual property protection to over 65 issued and pending patents worldwide, covering spectroscopy acquisition, data processing, and analytics.

•2mo ago

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Aclarion announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology. The platform uses Magnetic Resonance Spectroscopy to quantify chemical biomarkers associated with disc pain, demonstrating a 97% surgical success rate when Nociscan-positive discs are treated. CEO Brent Ness noted that the addition of the nationally recognized neurosurgery center reflects growing adoption momentum for the company's diagnostic technology.

•2mo ago

Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026

Aclarion reported 141% year-over-year scan volume growth in the first half of 2026, alongside a 71% sequential increase, signaling accelerating clinical adoption of its Nociscan platform. Commercial momentum expanded in the U.K. with reimbursement coverage secured from major insurers including Vitality, AXA, and Aviva, while the U.S. Market Access Program launched in partnership with PRIA Healthcare. The company ended the period with a strengthened balance sheet of $16.3 million in cash and no debt, providing a cash runway into the second half of 2027 to support the ongoing CLARITY trial.

•3mo ago

Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice

Aclarion presented two abstracts at the ASPN Annual Meeting highlighting the clinical utility of Nociscan in real-world practice and surgical decision support. A prospective study of 20 patients demonstrated successful integration of MR Spectroscopy into clinical workflows, while a separate case study reported 95% pain relief following Nociscan-guided basivertebral nerve ablation. Management emphasized that these findings underscore the breadth of Nociscan's applications in identifying pain sources across different treatment pathways.

•3mo ago

Aclarion Announces Texas Spine Care Center as New CLARITY Site

Aclarion added Texas Spine Care Center as a new clinical site for its CLARITY trial, expanding the network evaluating its Nociscan diagnostic platform. The study is a 300-patient, prospective, randomized trial designed to demonstrate Nociscan's ability to improve surgical outcomes for chronic low back pain. The company expects an initial internal data readout and public disclosure of early interim results in Q4 2026.

•3mo ago

Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub

Aclarion will present at the Planet MicroCap Las Vegas conference on June 17, 2026, hosted by Executive Chairman Jeff Thramann. The company highlighted recent progress including triple-digit annual growth in Nociscan adoption and a strengthened IP footprint with 64 issued and pending patents. Aclarion also announced a $2.5 million share repurchase program and noted its cash runway extends into the second half of 2027, with interim CLARITY trial results expected in Q4 2026.

•4mo ago

Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform

Aclarion has launched a Market Access Program in partnership with PRIA Healthcare to advance reimbursement and commercial adoption of its AI-powered Nociscan platform for chronic low back pain. The collaboration leverages PRIA’s expertise in payer engagement, prior authorization, and appeals management to streamline the reimbursement process for U.S. physicians and health systems. Nociscan has already secured payer approval from three of the top four private insurance companies in the UK, providing a validated foundation for Aclarion’s U.S. expansion strategy.

•4mo ago

Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal

Aclarion’s Board of Directors unanimously rejected an unsolicited acquisition proposal from Echo Lake Capital. The board determined the $4.00 per share offer significantly undervalued the company and would disproportionately benefit Echo Lake by allowing it to acquire Aclarion’s cash and assets at a discount. Management remains committed to pursuing credible paths to value creation and is open to proposals that reflect the company’s intrinsic value and strategic potential.

•4mo ago

Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation

Aclarion has partnered with the Institute of Neuro Innovation (INI) in Los Angeles to expand the availability of its Nociscan diagnostic platform. The agreement enables INI, led by neurosurgeon Amir Vokshoor, to generate real-world evidence comparing Nociscan’s chemical biomarker data with bone metabolic insights from SPECT-CT. This move supports Aclarion’s scalable growth strategy by adding a high-profile clinical site and building data assets critical for payer and provider adoption.

•4mo ago

Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study

Aclarion announced that its Nociscan MRS technology was utilized in an NIH-funded study that won the 2026 ISSLS Best Paper Award. The study, conducted by investigators at the University of Zurich, UCSF, and the REACH Center, used Nociscan’s methodology to measure intradiscal propionic acid in patients with Modic type 1 changes. Findings suggest that elevated propionic acid levels identify a patient subgroup with distinct systemic immune activation, potentially expanding Nociscan’s clinical utility beyond surgical decision support to include immune-associated pain stratification.

•5mo ago

Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal

Aclarion responded to an unsolicited acquisition proposal from Echo Lake Capital, which offered $4.00 per share in cash and contingent value rights. The Board stated it will carefully evaluate the proposal but emphasized that the current market valuation does not fully reflect the strength of its platform. To underscore this conviction, the Board authorized a share repurchase program, signaling a belief that the stock is undervalued and serving as a defensive measure against the activist's bid.

•5mo ago

Echo Lake Capital Offers To Acquire Aclarion Inc.

Echo Lake Capital has submitted a formal unsolicited proposal to acquire 100% of Aclarion Inc. (ACON) for $4.00 per share in cash, representing a 28% premium to the latest closing price. The offer includes a contingent value right for shareholders to receive 80% of net proceeds from the sale of Aclarion's Nociscan asset, contingent on the board delaying the annual shareholder meeting and maintaining at least $15 million in net cash. The proposal is accompanied by a scathing letter from activist investor Ephraim Fields, alleging that the board has destroyed 99% of shareholder value since the IPO while enriching themselves with $5.6 million in compensation, despite owning only 25 shares collectively. Fields also accuses certain directors of violating federal securities laws and failing to disclose material personal IRS tax liens, suggesting the board lacks the financial incentive or integrity to maximize shareholder value.

•5mo ago

Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment

Aclarion added Lanman Spinal Neurosurgery, a high-volume private practice in Beverly Hills, as a clinical site for its ongoing CLARITY trial evaluating Nociscan. The inclusion of a private practice site is designed to accelerate enrollment in the 300-patient randomized study, which targets an initial public disclosure of early interim results in Q4 2026. Management highlighted that this expansion reflects growing demand for precise, data-driven tools in everyday clinical practice to improve surgical outcomes for chronic low back pain.

•5mo ago

Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine

Aclarion signed a second commercial agreement with Weill Cornell Medicine to utilize its Nociscan platform in a prospective randomized trial focused on degenerative disc disease. The study, led by neurosurgeon Dr. Roger Härtl, will evaluate long-term effects of lumbar surgery with bone marrow aspirate concentrate to better understand disc health and pain biomarkers over a two-year period. Management highlighted the partnership with a top-tier research center as a key step in demonstrating Nociscan's ability to illuminate chemical aspects of disc degeneration not visible via traditional imaging.

•5mo ago

Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption

Aclarion reported accelerating clinical adoption of its Nociscan platform with Q1 scan volume growing 196% year-over-year and 64% sequentially, driven by new account activations and deeper utilization within existing sites. The company strengthened its financial position with $19.0 million in cash, no debt, and the announcement of a $2.5 million share repurchase program, providing a cash runway into the second half of 2027. Key upcoming catalysts include the interim readout of the CLARITY randomized trial in late 2026 and ongoing reimbursement discussions with U.S. payers following coverage by major U.K. insurers.

•6mo ago